Patent Issued for Composition for Promoting Remyelination in Nerve Cells

[unable to retrieve full-text content]

By a News Reporter-Staff News Editor at Pain & Central Nervous System Week — SAMSUNG ELECTRONICS CO., LTD. (Suwon-si, KR) has been issued patent number 9782371, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors (see also SAMSUNG ELECTRONICS CO., LTD.).

The patent’s inventors are Lee, Yunil (Yongin-si, KR); Kim, Suhyun (Ansan-si, KR); Park, Haechul (Ansan-si, KR); Park, Sangchul (Seongnam-si, KR).

This patent was filed on July 5, 2016 and was published online on October 10, 2017.

From the background information supplied by the inventors, news correspondents obtained the following quote: “The present disclosure relates to a composition for preventing or treating a disease associated with demyelination of nerve cells in a mammal, a composition for promoting remyelination or suppressing demyelination of nerve cells in a mammal, a composition for reducing expression of PMP22 in nerve cells of a mammal, a method of preventing or treating a disease associated with demyelination of nerve cells in a mammal, a method of promoting remyelination or suppressing demyelination of nerve cells in a mammal, and a method of reducing expression of PMP22 in nerve cells of a mammal.

“Demyelinating diseases are diseases of the nervous system in which the myelin sheaths of neurons are damaged. This damage impairs the conduction of signals in the affected nerves, which sequentially causes deficiency in sensation, movement, cognition, or other functions depending on which nerves are affected. Demyelinating diseases may include diseases affecting the central nervous system and peripheral nervous system. Demyelinating diseases of the peripheral nervous system include Guillain-Barre Syndrome and Charcot Marie Tooth (CMT) diseases. Demyelinating diseases of the central nervous system include multiple sclerosis. Ascorbic acid has been shown to be effective against peripheral nerve disease in animal models; however, this compound fails in clinical tests. Therefore, there is a need for a drug for the fundamental treatment of demyelinating diseases.”

Supplementing the background information on this patent, NewsRx reporters also obtained the inventors’ summary information for this patent: “Provided is a composition for preventing or treating a disease associated with demyelination of nerve cells in a mammal, the composition comprising 2,5-dihydroxybenzenesulfonic acid, or a pharmaceutically acceptable salt or solvate thereof.

“Provided is a composition for promoting remyelination or suppressing demyelination of nerve cells in a mammal, the composition comprising 2,5-dihydroxybenzenesulfonic acid, or a pharmaceutically acceptable salt or solvate thereof.

“Provided is a composition for reducing expression of peripheral myelin protein 22 (PMP22) in nerve cells of a mammal, the composition comprising 2,5-dihydroxybenzenesulfonic acid, or a pharmaceutically acceptable salt or solvate thereof.

“Provided is a method of preventing or treating a disease associated with demyelination of a nerve cell in a mammal, the method comprising administering an effective amount of 2,5-dihydroxybenzenesulfonic acid or a pharmaceutically acceptable salt or solvate thereof into the mammal to thereby prevent or treat a disease associated with demyelination of the nerve cell of the mammal.

“Provided is a method of promoting remyelination or suppressing demyelination of a nerve cell in a mammal, the method comprising administering an effective amount of 2,5-dihydroxybenzenesulfonic acid or a pharmaceutically acceptable salt or solvate thereof into the mammal to thereby promote remyelination or suppress demyelination in the nerve cell of the mammal.

“Provided is a method of reducing expression of PMP22 in a nerve cell of a mammal, the method comprising administering an effective amount of 2,5-dihydroxybenzenesulfonic acid or a pharmaceutically acceptable salt or solvate thereof into a mammal to thereby reduce expression of PMP22 in the nerve cell of the mammal.

“Additional aspects will be set forth in part in the description which follows and, in part, will be apparent from the description, or may be learned by practice of the presented exemplary embodiments.”

For the URL and additional information on this patent, see: Lee, Yunil; Kim, Suhyun; Park, Haechul; Park, Sangchul. Composition for Promoting Remyelination in Nerve Cells Comprising 2,5-Dihydroxybenzenesulfonic Acid and Use. U.S. Patent Number 9782371, filed July 5, 2016, and published online on October 10, 2017. Patent URL: http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=9782371.PN.&OS=PN/9782371RS=PN/9782371

Keywords for this news article include: Central Nervous System, SAMSUNG ELECTRONICS CO. LTD.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC


Source: Samsung

Patent Issued for Composition for Promoting Remyelination in Nerve Cells
User Rating: 0 (0 votes)